TCRX vendidas en apertura a 5,10 las que tenía de media a unos 3,88 DNA ayer doblé mi posición a 1,33$ que tenia varias entrada ( la primera a 9) pero eran muy simbólicas PLSE ( la de bob duggan) vendo a 8 las que tenia a media a 5, ( primera entrada 16, asi que no me quejaré)
no estoy operando mucho, al no bajar más la cosa para provechar, ni subir... modo stand by pero mantengo la cartera hasta que florezca si debe, 4 se me han ido al otc , posiciones pequeñas
de las que tengo alguna lo petará ya sea en un año, 3 o 5 o 10, espero, y compensará y si hay debacle, mantengo mi artillería pesada pacientemente, dispuesta a entrar a lo grande en algunas saludos!
que pesados los de MTSL , ya van dos mails de estos esta semana ... pues eso, que biotech is back! ale venga a comprar to' !!
Dear Biotech Investor,
Biotech is back with multiple premium buyouts in the last few weeks; Prometheus was bought by Merck for $11 billion, a 75% premium, in a bidding war with other Big Pharmas. Merck lost out to Pfizer who just bought SGEN for $40 billion for their expertise in new cancer drugs, specifically ADCs like Padcev which are targeted monoclonal antibodies with killing agents attached.
With interest rates peaking/about to peak, the biotech sector is poised to move higher. Big Pharma knows this and is buying biotech before the big move. We currently have a recommendation that makes 2nd generation ADCs and in fact has a better and safer Padcev in development, one of the key ADCs Merck acquired from SGEN. We also have a new recommendation in the hottest sector in drug development; obesity/type 2 diabetes that we would love to share with you.
Subscribe today to access both of these cutting edge biotech recommendations.
